Site icon Market Globalist

Cocrystal Pharma Inc. (COCP) stock soars during current market. Here’s what you should know

PTON Stock

PTON Stock

Cocrystal Pharma Inc. (NASDAQ: COCP) stock gains by 17.44% in the current market trading session. Cocrystal Pharma, Inc. is a clinical-stage biotechnology firm focused on finding and creating new antiviral medicines that tackle coronaviruses (particularly SARS-CoV-2), influenza viruses, hepatitis C virus, and norovirus replication.

>> 7 Top Picks for the Post-Pandemic Economy << 

Significant Development in COCP stock

SARS-CoV-2 3CL protease leads CDI-45205 and various analogs demonstrated significant in vitro efficacy against the SARS-CoV-2 Delta (India/B.1.617.2) and Gamma (Brazil/P.1) variants, according to Cocrystal Pharma. CDI-45205 and analogs showed broad-spectrum efficacy against the SARS-CoV-2 Alpha and Beta variants, exceeding the activity shown with the Wuhan strain, according to Cocrystal.

Read More

COCP’s unique drug discovery platform technology is still being used to create SARS-CoV-2 oral protease inhibitors and replication inhibitors. Cocrystal’s method to drug development offers a one-of-a-kind avenue to developing broad-spectrum coronavirus antivirals for SARS-CoV-2 and other emerging variants.

What is CDI-45205?

Cocrystal stated in December 2020 that it has chosen CDI-45205 as their main coronavirus research candidate from a pool of protease inhibitors received under the KSURF agreements. In intraperitoneal injection pharmacokinetic studies in mice and rats, CDI-45205 showed good bioavailability and no cytotoxicity against a range of human cell lines. In addition, CDI-45205 has a high synergistic impact with remdesivir.  Furthermore, solid evidence animal research found that daily injections of CDI-45205 in MERS-CoV-infected mice had excellent in vivo effectiveness. Cocrystal is continuing to test CDI-45205 after receiving good preliminary pharmacokinetic data.

>> 7 Top Picks for the Post-Pandemic Economy << 

Sam Lee, Cocrystal’s President, and interim co-CEO stated,

These SARS-CoV-2 in vitro data also suggest that Cocrystal’s SARS-CoV-2 3CL protease inhibitor CDI-45205 might be a viable therapy for COVID-19 induced by SARS-CoV-2. It’s developing variants, such as the fast-spreading Delta version, which is quickly becoming the most common COVID-19 variant worldwide. CDI-45205 previously shown good in vivo effectiveness in a MERS-CoV-2 infected animal model, thus broad-spectrum action against these SARS-CoV-2 variants is quite promising.

Exit mobile version